Tasigna (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia.

Trial Profile

Tasigna (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2015

At a glance

  • Drugs Nilotinib (Primary) ; Daunorubicin; Prednisolone; Prednisolone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jun 2015 Results published in the Blood.
    • 29 Jan 2014 Status changed from recruiting to completed.
    • 10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top